115 related articles for article (PubMed ID: 10391533)
1. Influence of chemotherapy on the expression of p53, HER-2/neu and proliferation markers in ovarian cancer.
Nijman HW; Kenemans P; Poort-Keesom RJ; Verstraeten RA; Mensdorff-Pouilly S; Verheijen RH; Melief CJ; Hilgers J; Meijer CJ
Eur J Obstet Gynecol Reprod Biol; 1999 Apr; 83(2):201-6. PubMed ID: 10391533
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of immunohistochemical expression of topoisomerase alpha II, MIB-1, p53, E-cadherin, retinoblastoma gene protein product, and HER-2/neu in adrenal and extra-adrenal pheochromocytomas.
Gupta D; Shidham V; Holden J; Layfield L
Appl Immunohistochem Mol Morphol; 2000 Dec; 8(4):267-74. PubMed ID: 11127918
[TBL] [Abstract][Full Text] [Related]
3. Evidence for a dose-response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy.
Levesque MA; Katsaros D; Massobrio M; Genta F; Yu H; Richiardi G; Fracchioli S; Durando A; Arisio R; Diamandis EP
Clin Cancer Res; 2000 Aug; 6(8):3260-70. PubMed ID: 10955812
[TBL] [Abstract][Full Text] [Related]
4. The prognostic and predictive value of immunohistochemically detected HER-2/neu overexpression in 361 patients with ovarian cancer: a multicenter study.
Riener EK; Arnold N; Kommoss F; Lauinger S; Pfisterer J
Gynecol Oncol; 2004 Oct; 95(1):89-94. PubMed ID: 15385115
[TBL] [Abstract][Full Text] [Related]
5. [Relationship between expressions of p53, c-erbB2 genes, proliferating cell nuclear antigen and prognosis of patients with ovarian epithelial carcinoma].
Li JD; Li MD; Li YF; Huang X; Liu JH; Liu FY; Zhang CQ
Ai Zheng; 2002 Mar; 21(3):292-6. PubMed ID: 12451998
[TBL] [Abstract][Full Text] [Related]
6. Her-2/neu expression in ovarian cancer: pre- and postexposure to platinum chemotherapy.
Peethambaram PP; Cliby WA; Lubiniecki G; Clayton AC; Roche PC; Iturria SJ; Hartmann LC; Hellström I; Strome SE
Gynecol Oncol; 2003 Apr; 89(1):99-104. PubMed ID: 12694661
[TBL] [Abstract][Full Text] [Related]
7. Prognostic values of p53 and HER-2/neu coexpression in invasive bladder cancer in Taiwan.
Tsai YS; Tzai TS; Chow NH; Yang WH; Tong YC; Lin JS; Chang CC; Cheng HL; Lin YM
Urol Int; 2003; 71(3):262-70. PubMed ID: 14512646
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of immunohistochemical expressions of p53, HER-2/neu, and bcl-2 in stage I non-small-cell lung cancer.
Han H; Landreneau RJ; Santucci TS; Tung MY; Macherey RS; Shackney SE; Sturgis CD; Raab SS; Silverman JF
Hum Pathol; 2002 Jan; 33(1):105-10. PubMed ID: 11823980
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of human epidermal growth factor receptor 2 (Her-2)/neu in patients with advanced ovarian cancer treated with platinum/paclitaxel as first-line chemotherapy: a retrospective evaluation of the AGO-OVAR 3 Trial by the AGO OVAR Germany.
Pfisterer J; Du Bois A; Bentz EK; Kommoss F; Harter P; Huober J; Schmalfeldt B; Burchardi N; Arnold N; Hilpert F
Int J Gynecol Cancer; 2009 Jan; 19(1):109-15. PubMed ID: 19258951
[TBL] [Abstract][Full Text] [Related]
10. Mitochondrial DNA alterations correlate with the pathological status and the immunological ER, PR, HER-2/neu, p53 and Ki-67 expression in breast invasive ductal carcinoma.
Lin CS; Chang SC; Ou LH; Chen CM; Hsieh SS; Chung YP; King KL; Lin SL; Wei YH
Oncol Rep; 2015 Jun; 33(6):2924-34. PubMed ID: 25845386
[TBL] [Abstract][Full Text] [Related]
11. In vitro chemoresistance and biomarker profiles are unique for histologic subtypes of epithelial ovarian cancer.
Cloven NG; Kyshtoobayeva A; Burger RA; Yu IR; Fruehauf JP
Gynecol Oncol; 2004 Jan; 92(1):160-6. PubMed ID: 14751152
[TBL] [Abstract][Full Text] [Related]
12. Expression of cyclooxygenase-2 (COX-2), receptors for estrogen (ER), and progesterone (PR), p53, ki67, and neu protein in endometrial cancer.
Ferrandina G; Ranelletti FO; Gallotta V; Martinelli E; Zannoni GF; Gessi M; Scambia G
Gynecol Oncol; 2005 Sep; 98(3):383-9. PubMed ID: 15979129
[TBL] [Abstract][Full Text] [Related]
13. Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis.
de Graeff P; Crijns AP; de Jong S; Boezen M; Post WJ; de Vries EG; van der Zee AG; de Bock GH
Br J Cancer; 2009 Jul; 101(1):149-59. PubMed ID: 19513073
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of hormonal receptors, p53, ki67 and HER2/neu expression in epithelial ovarian carcinoma.
García-Velasco A; Mendiola C; Sánchez-Muñoz A; Ballestín C; Colomer R; Cortés-Funes H
Clin Transl Oncol; 2008 Jun; 10(6):367-71. PubMed ID: 18558584
[TBL] [Abstract][Full Text] [Related]
15. Overexpression and relationships of HER-2/neu, epidermal growth factor receptor, p53, Ki-67, and tumor necrosis factor alpha in epithelial ovarian cancer.
Goff BA; Shy K; Greer BE; Muntz HG; Skelly M; Gown AM
Eur J Gynaecol Oncol; 1996; 17(6):487-92. PubMed ID: 8971524
[TBL] [Abstract][Full Text] [Related]
16. Expression of p53 and selected proliferative markers (Ki-67, MCM3, PCNA, and topoisomerase IIα) in borderline ovarian tumors: Correlation with clinicopathological features.
Ciepliński K; Jóźwik M; Semczuk-Sikora A; Gogacz M; Lewkowicz D; Ignatov A; Semczuk A
Histol Histopathol; 2018 Feb; 33(2):171-179. PubMed ID: 28493257
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of HER-2, p53 and Bcl-2 in patients with epithelial ovarian cancer.
Malamou-Mitsi V; Crikoni O; Timotheadou E; Aravantinos G; Vrettou E; Agnantis N; Fountzilas G
Anticancer Res; 2007; 27(2):1157-65. PubMed ID: 17465257
[TBL] [Abstract][Full Text] [Related]
18. Expression of EGFR, HER-2/neu, P53, and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas.
Khalifa MA; Mannel RS; Haraway SD; Walker J; Min KW
Gynecol Oncol; 1994 Apr; 53(1):84-92. PubMed ID: 7909788
[TBL] [Abstract][Full Text] [Related]
19. p53 and HER2/neu expression in relation to chemotherapy response in patients with non-small cell lung cancer.
Fijołek J; Wiatr E; Rowińska-Zakrzewska E; Giedronowicz D; Langfort R; Chabowski M; Orłowski T; Roszkowski K
Int J Biol Markers; 2006; 21(2):81-7. PubMed ID: 16847810
[TBL] [Abstract][Full Text] [Related]
20. DNA hypermethylation, Her-2/neu overexpression and p53 mutations in ovarian carcinoma.
Feng Q; Deftereos G; Hawes SE; Stern JE; Willner JB; Swisher EM; Xi L; Drescher C; Urban N; Kiviat N
Gynecol Oncol; 2008 Nov; 111(2):320-9. PubMed ID: 18757082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]